ClinicalTrials.gg
CompletedNCT07779291Updated Aug 21, 2026

Research on Predicting Aortic Remodeling Following TEVAR for Type B Aortic Dissection Based on VDM and CFD

An observational study in Type B Aortic Dissection, Tevar and CFD, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Completed at 3 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,000
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This study proposes a retrospective analysis that systematically integrates multidimensional biomechanical and anatomical data to construct an early and accurate predictive model for adverse aortic remodeling following thoracic endovascular aortic repair (TEVAR) in patients with Type B aortic dissection (TBAD). Postoperative follow-up CTA images will be analyzed using vascular deformation mapping (VDM) technology, which enables quantitative assessment of regional aortic deformation and strain evolution through high-precision three-dimensional registration, thereby overcoming the limitations of conventional diameter-based measurements. Concurrently, patient-specific computational fluid dynamics (CFD) models will be reconstructed from preoperative CTA data to simulate the hemodynamic environment within the dissected aorta, extracting key parameters including wall shear stress, flow velocity, and pressure distribution to quantify the mechanical forces driving vascular remodeling. Furthermore, the anatomical characteristics of entry tears-including their number, spatial distribution, and size-will be systematically characterized. By integrating these three dimensions of indicators and employing multivariable regression and machine learning algorithms, independent risk factors significantly associated with adverse events such as false lumen aneurysmal expansion, aortic rupture, and recurrent dissection will be identified, ultimately establishing a comprehensive predictive model that combines sensitivity, objectivity, and clinical feasibility. The development of this model is expected to provide clinicians with quantitative decision support for early identification of high-risk patients, formulation of individualized surveillance strategies, and implementation of timely interventions, thereby substantially improving the long-term prognosis and quality of life for TBAD patients following TEVAR.

Read the detailed description

Inclusion Criteria: (1) Age between 18 and 85 years, male or non-pregnant female. (2) CTA-confirmed diagnosis of Type B aortic dissection, classified as acute uncomplicated dissection. (3) Underwent TEVAR (thoracic endovascular aortic repair) procedure. (4) At least one preoperative and three postoperative CTA examinations available, with imaging coverage extending cranially to include the brachiocephalic trunk, left common carotid artery, and the origin of the left subclavian artery, and caudally to cover the origins of the internal and external iliac arteries.

Exclusion Criteria: (1) Age \<18 or >85 years. (2) Traumatic or iatrogenic dissection, or isolated aortic aneurysm. (3) Chronic or complicated dissection. (4) Penetrating aortic ulcer (PAU) or intramural hematoma (IMH), as well as localized dissection. (5) Connective tissue disorders, such as Marfan syndrome. (6) Prior history of cardiac or aortic surgery. (7) Absence of signed surgical informed consent. (8) Insufficient CTA examinations or inadequate imaging coverage/quality. (9) Failure of image registration precluding completion of the VDM analysis workflow.

02

Conditions studied

  • Type B Aortic Dissection
  • Tevar
  • CFD

Keywords

  • Type B aortic dissection
  • TEVAR
  • adverse aortic remodeling
  • vascular deformation mapping
  • computational fluid dynamics
03

In context

Lead sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 104 studies on the registry; 70 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study population comprises patients diagnosed with acute uncomplicated Type B aortic dissection who underwent thoracic endovascular aortic repair (TEVAR) at a single center. Eligible patients were aged 18 to 85 years, male or non-pregnant female, and had at least one preoperative and three postoperative CTA examinations with adequate imaging coverage from the brachiocephalic trunk to the iliac arteries. Patients with traumatic or iatrogenic dissection, chronic or complicated dissection, penetrating aortic ulcer (PAU), intramural hematoma (IMH), localized dissection, connective tissue disorders (e.g., Marfan syndrome), prior cardiac or aortic surgery, insufficient imaging quality, or failed image registration for VDM analysis were excluded. A total of 1000 patients were enrolled and followed for up to 5 years post-TEVAR to assess adverse aortic remodeling outcomes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

(1) Age between 18 and 85 years, male or non-pregnant female. (2) CTA-confirmed diagnosis of Type B aortic dissection, classified as acute uncomplicated dissection. (3) Underwent TEVAR (thoracic endovascular aortic repair) procedure. (4) At least one preoperative and three postoperative CTA examinations available, with imaging coverage extending cranially to include the brachiocephalic trunk, left common carotid artery, and the origin of the left subclavian artery, and caudally to cover the origins of the internal and external iliac arteries.

Exclusion criteria

Exclusion Criteria:

(1) Age \<18 or >85 years. (2) Traumatic or iatrogenic dissection, or isolated aortic aneurysm. (3) Chronic or complicated dissection. (4) Penetrating aortic ulcer (PAU) or intramural hematoma (IMH), as well as localized dissection. (5) Connective tissue disorders, such as Marfan syndrome. (6) Prior history of cardiac or aortic surgery. (7) Absence of signed surgical . (8) Insufficient CTA examinations or inadequate imaging coverage/quality. (9) Failure of image registration precluding completion of the VDM analysis workflow.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,000 participants (actual)
Patient registry
No

Groups and cohorts

  • TEVAR-TBAD Cohort

    TEVAR using commercially available stent-grafts via femoral access, covering the primary entry tear to promote false lumen thrombosis and aortic remodeling. This single-arm cohort includes acute uncomplicated TBAD patients treated with TEVAR, with adequate pre- and post-operative CTA imaging. Exclusions include connective tissue disorders, traumatic/iatrogenic dissection, PAU/IMH, prior aortic surgery, and insufficient imaging quality. The cohort is analyzed retrospectively using VDM, CFD, and tear morphology to predict adverse remodeling outcomes

    Procedure: Thoracic Endovascular Aortic Repair

Interventions

  • ProcedureThoracic Endovascular Aortic Repair

    Thoracic endovascular aortic repair (TEVAR) with commercially available stent-graft devices, implanted via femoral arterial access under fluoroscopic guidance. The intervention involves covering the primary entry tear with a stent-graft to redirect blood flow into the true lumen.

06

What researchers measure

Primary outcomes

  1. Composite of Adverse Aortic Remodeling

    A composite endpoint defined as the occurrence of any of the following events during follow-up: (1) aneurysmal dilation of the stented or distal aorta to ≥5.0 cm; (2) aneurysmal dilation rate ≥0.5 cm/year; (3) rupture or signs of imminent rupture; (4) visceral and/or lower limb malperfusion; (5) distal stent-induced new entry (d-SINE); (6) Type I, II, III, or R endoleak.

    Time frame: Up to 5 years post-procedure

Secondary outcomes

  1. All-Cause Mortality

    Death from any cause during follow-up.

    Time frame: Up to 5 years post-procedure

  2. Aortic-Related Mortality

    Death related to progression of aortic dissection or complications following TEVAR during follow-up.

    Time frame: Up to 5 years post-procedure

  3. Aortic-Related Secondary Intervention Rate

    Rate of secondary interventions related to progression of aortic dissection or complications from the initial TEVAR procedure. Indications for secondary intervention include: Type I/III endoleak, Type II endoleak with concomitant false lumen aneurysmal dilation, retrograde Type A dissection (RTAD), distal stent-induced new entry (d-SINE) causing pain or persistent false lumen perfusion, distal aneurysmal dilation, and left subclavian artery (LSA) steal syndrome due to LSA coverage during the initial intervention. Secondary intervention strategies include: endovascular approaches (repeat stent-graft implantation, branch artery stenting, chimney/periscope techniques, coil embolization) and open surgical approaches (artificial vascular graft replacement, supra-aortic or visceral branch artery bypass/transposition).

    Time frame: Up to 5 years post-procedure

  4. Visceral Artery Branch Lumen Loss Rate

    Rate of visceral artery branch lumen loss during follow-up, assessed by serial CTA imaging.

    Time frame: Up to 5 years post-procedure

  5. False Lumen Thrombosis Status

    Degree of false lumen thrombosis assessed by serial CTA imaging during follow-up. Thrombosis status is categorized based on the extent of thrombus formation within the false lumen.

    Time frame: Up to 5 years post-procedure

  6. Aortic-Related Adverse Events (AAEs) Rate

    Rate of aortic-related adverse events (AAEs) during follow-up. AAEs are defined as a composite of: aortic-related death, major adverse cardiovascular events, stroke, acute renal insufficiency, rupture, spinal cord ischemia, mesenteric ischemia, lower limb ischemia, retrograde Type A dissection (RTAD), distal stent-induced new entry (d-SINE), stent-graft migration, stent-graft infection, and access site complications.

    Time frame: Up to 5 years post-procedure

07

Study locations

3 sites
  • Zhongshan Hospital, Fudan University
    Shanghai, Shanghai Municipality 200032, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Dec 2025, 71 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2026
First posted
Aug 21, 2026
StartActual
Jan 1, 2020
Primary completionActual
Dec 31, 2025
CompletionActual
Feb 1, 2026
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07779291
Collaborators
First Affiliated Hospital of Wenzhou Medical University, Fudan University
Responsible party
Sponsor
First posted
Aug 21, 2026
Start date
Jan 1, 2020
Primary completion
Dec 31, 2025
Completion
Feb 1, 2026
Last update
Aug 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion